Additief antiproteinurisch effect van de vitamine D analoog paricalcitol.
- Conditions
- proteinuriaproteinuriealbuminuriaalbuminuriechronic kidney diseasechronisch nierfalennon-diabetic renal diseaseniet-diabetische nierziekteparicalcitolzemplarvitamin D receptor activatorvitamine D receptor activatorvitamin Dvitamine D
- Registration Number
- NL-OMON22539
- Lead Sponsor
- niversity Medical Center Groningen
- Brief Summary
Publication policy is in agreement with the CCMO publication statement. Nor the sponsors, nor the principal investigator has a right of veto regarding the way of publishing the results.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
1. Male and female patients;
2. Non-diabetic renal disease as established by history, serum biochemistry tests and/or renal biopsy;
Exclusion Criteria
1. Uncontrolled hypertension, hyperkalemia (potassium >6.0 mmol/l, cardiovascular disease (myocardial infarction, unstable angina, percutanous transluminal coronary angioplasty, coronary artery bypass grafting, or stroke within last 6 months, heart failure NYHA III-IV), Diabetes Mellitus;
2. Epilepsy;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Albuminuria (24-hour urinary albumin excretion).
- Secondary Outcome Measures
Name Time Method 1. Mean arterial pressure (MAP);<br /><br>2. Serum creatinine / creatinine clearance;<br /><br>3. Plasma renin activity (PRA);<br /><br>4. Renal hemodynamics (measured GFR, ERPF).